American Society of Clinical oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 6, 2010, Pages 907-922

  Hammond, M Elizabeth H ^a   Hayes, Daniel F ^a   Dowsett, Mitch ^a   Allred, D Craig ^a   Hagerty, Karen L ^a   Badve, Sunil ^a   Fitzgibbons, Patrick L ^a   Francis, Glenn ^a   Goldstein, Neil S ^a   Hayes, Malcolm ^a   Hicks, David G ^a   Lester, Susan ^a   Love, Richard ^a   Mangu, Pamela B ^a   McShane, Lisa ^a   Miller, Keith ^a   Osborne, C Kent ^a   Paik, Soonmyung ^a   Perlmutter, Jane ^a   Rhodes, Anthony ^a   Sasano, Hironobu ^a   Schwartz, Jared N ^a   Sweep, Fred C G ^a   Taube, Sheila ^a   Torlakovic, Emina Emilia ^a   Valenstein, Paul ^a   Viale, Giuseppe ^a   Visscher, Daniel ^a   Wheeler, Thomas ^a   Williams, R Bruce ^a   Wittliff, James L ^a   Wolff, Antonio C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ALGORITHM; ARTICLE; BREAST TUMOR; FEMALE; HEALTH CARE PLANNING; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL SOCIETY; METABOLISM; METHODOLOGY; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; UNITED STATES;

ALGORITHMS; BREAST NEOPLASMS; FEMALE; GUIDELINES AS TOPIC; HEALTH PLANNING GUIDELINES; HUMANS; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 77953198056     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007
2. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18-43, 2007
3. Fitzgibbons PL, Murphy DA, Hammond MEH, et al: Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med (in press)
4. McCarty KS Jr, Miller LS, Cox EB, et al: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721, 1985
5. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74: 1445-1451, 1996
6. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999
7. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89: 111-117, 2000
8. Thomson CS, Twelves CJ, Mallon EA, et al: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11: 419-429, 2002
9. Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 98: 1571-1581, 2006
10. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17: 1545-1554, 2004
11. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
12. Badve SS, Baehner FL, Gray RP, et al: Estrogen-and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26: 2473-2481, 2008
13. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25: 3846-3852, 2007
14. Viale G, Regan MM, Maiorano E, et al: Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors-International Breast Cancer Study Group. J Clin Oncol 26: 1404-1410, 2008
15. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24: 5637-5644, 2006
16. Phillips T, Murray G, Wakamiya K, et al: Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol 15: 325-331, 2007
17. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 26: 1059-1065, 2008
18. McGuire W, Carbone PP, Sears ME, et al: Estrogen receptors in human breast cancer, in McGuire WL, Carbone PP, Vollmer EP (eds) : Estrogen Receptors in Human Breast Cancer. New York, NY, Raven Press, 1975, pp 1-7
19. Osborne CK, Yochmowitz MG, Knight WA 3rd, et al: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888, 1980
20. Knight WA 3rd, Osborne CK, McGuire WL: Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab 9: 361-368, 1980
21. Cowen PN, Teasdale J, Jackson P, et al: Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay. Histopathology 17: 319-325, 1990
22. Stendahl M, Ryden L, Nordenskjold B, et al: High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 12: 4614-4618, 2006
23. Lockwood CA, Ricciardelli C, Raymond WA, et al: A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 84: 203-208, 1999
24. Esteban JM, Ahn C, Battifora H, et al: Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance. J Cell Biochem Suppl 19: 138-145, 1994
25. Yamashita H, Yando Y, Nishio M, et al: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13: 74-83, 2006
26. Jalava P, Kuopio T, Huovinen R, et al: Immunohistochemical staining of estrogen and progesterone receptors: Aspects for evaluating positivity and defining the cutpoints. Anticancer Res 25: 2535-2542, 2005
27. Ogawa Y, Moriya T, Kato Y, et al: Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cutoff point as the predictor for endocrine therapy. Breast Cancer 11: 267-275, 2004
28. Gown AM: Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. Am J Clin Pathol 121: 172-174, 2004
29. Nenci I, Beccati MD, Piffanelli A, et al: Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique. J Steroid Biochem 7: 505-510, 1976
30. Diaz LK, Sneige N: Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 12: 10-19, 2005
31. Yaziji H, Taylor CR, Goldstein NS, et al: Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol 16: 513-520, 2008
32. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120: 86-92, 2003
33. Taylor CR, Levenson RM: Quantification of immunohistochemistry: Issues concerning methods, utility and semiquantitative assessment II. Histopathology 49: 411-424, 2006
34. Gutman S: Regulatory issues in tumor marker development. Semin Oncol 29: 294-300, 2002